大型3型/4型胃癌に対する術前S-1＋CDDP＋DTX併用療法による第II相試験（OGSG 1402）：5年長期成績
2025
Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial
高度リンパ節転移を伴う進行胃癌に対する周術期Capecitabine＋Oxaliplatin (CapeOx)療法の第II相試験(OGSG1701)の最終生存解析
A Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for large type 3 or type 4 gastric cancer Final outcomes (OGSG1902)
胃癌へのICI導入後におけるConversion手術の実際 -高齢者に着目したリアルワールドデータ(OGSG2301)-
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)
Three-Year and Five-Year Outcomes of a Phase II Study of Perioperative CapeOxTherapy for Advanced Gastric Cancer with Extensive Lymph Node Metastasis (OGSG1701)
A Multicenter Phase II Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)
Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Final outcomes of the phase II OGSG1902 trial